Among hospitalized patients with community-acquired pneumonia, those treated with azithromycin plus beta-lactams had lower in-hospital mortality and mortality rates at 30 and 90 days post-admission ...
EurekAlert!: Antibiotics initiated for suspected community-acquired pneumonia even when chest radiography results are negative
Antibiotics initiated for suspected community-acquired pneumonia even when chest radiography results are negative
Whether the antiinflammatory and immunomodulatory effects of glucocorticoids may decrease mortality among patients with severe community-acquired pneumonia is unclear. In this phase 3, multicenter, ...
A multicenter target trial emulation found that for eligible patients hospitalized with community-acquired pneumonia (CAP), health outcomes were similar whether they received a three- to four-day ...
In this issue of CMAJ, Vardakas and colleagues1 present the findings of a meta-analysis of treatment strategies for community-acquired pneumonia. Because pneumonia is a leading cause of death in the ...
Yahoo Finance: Community Acquired Pneumonia Review 2020: Therapeutics Development, Drug Profiles, Dormant Projects and Product Development Milestones
Dublin, Aug. 25, 2020 (GLOBE NEWSWIRE) -- The "Community Acquired Pneumonia - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering. The Pharmaceutical and ...
Community Acquired Pneumonia Review 2020: Therapeutics Development, Drug Profiles, Dormant Projects and Product Development Milestones
This guideline covers diagnosing, assessing, and treating community-acquired and hospital-acquired pneumonia, including bacterial pneumonia secondary to COVID-19, in babies over 1 month (corrected ...
CMAJ: Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials
Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials
Pneumococcal polysaccharide conjugate vaccines prevent pneumococcal disease in infants, but their efficacy against pneumococcal community-acquired pneumonia in adults 65 years of age or older is ...